RK-pulsed allogeneic antigen-presenting cell therapy (RIKEN/Ambicion)

N/A

Report date: 2025/03/20 10:03:24

Base Information

Drug NameRK-pulsed allogeneic antigen-presenting cell therapy (RIKEN/Ambicion)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionImmunostimulantsNatural killer T-lymphocyte stimulants
TargetsUpdating
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRiken
China Registration ClassN/A

Develop Information

Active CompaniesRikenAmbicion
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A